{
    "nct_id": "NCT05050149",
    "official_title": "A Multicenter, Phase 2, Open-Label Study Evaluating The Safety And Efficacy of Sirolimus 3.9% Topical Gel (PTX-022) In The Treatment of Microcystic Lymphatic Malformations",
    "inclusion_criteria": "* Participants must be 6 years or older\n* Diagnosed with Microcystic Lymphatic Malformations\n* Able and willing to comply with all protocol-required activities\n* Willing and able to provide written informed consent\nHealthy volunteers allowed\nMust have minimum age of 6 Years",
    "exclusion_criteria": "* Any significant concurrent condition that could adversely affect participation.\n* Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications or to PTX-022\n* Patient's deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, including adherence to study drug administration and other protocol-required activities.",
    "miscellaneous_criteria": ""
}